Solid pharmaceutical compositions containing an integrase inhibitor
US9649311B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2010 |
| Grant date | May 16, 2017 |
| Priority date | — |
| Expiry date | Oct 21, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/209
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.